TD Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$87.3M Sell
1,115,730
-52,936
-5% -$3.61M 0.08% 205
2026
Q1
$75.5M Buy
1,168,666
+236,962
+25% +$16.7M 0.06% 230
2025
Q4
$62.7M Sell
931,704
-103,466
-10% -$6.96M 0.05% 270
2025
Q3
$75.9M Sell
1,035,170
-55,590
-5% -$3.69M 0.06% 240
2025
Q2
$56.7M Sell
1,090,760
-361,082
-25% -$20.5M 0.05% 289
2025
Q1
$92.6M Buy
1,451,842
+79,708
+6% +$4.63M 0.09% 198
2024
Q4
$65.6M Sell
1,372,134
-178,602
-12% -$9.16M 0.06% 264
2024
Q3
$88.3M Sell
1,550,736
-815,247
-34% -$46.7M 0.08% 229
2024
Q2
$124M Sell
2,365,983
-175,283
-7% -$7.69M 0.12% 165
2024
Q1
$103M Buy
2,541,266
+557,350
+28% +$20.9M 0.1% 194
2023
Q4
$73.3M Buy
1,983,916
+1,662,390
+517% +$62.6M 0.07% 228
2023
Q3
$12.3M Hold
321,526
0.01% 540
2023
Q2
$11.6M Hold
321,526
0.01% 563
2023
Q1
$12.3M Buy
321,526
+138,641
+76% +$6.5M 0.01% 554
2022
Q4
$10.4M Buy
+182,885
New +$9.36M 0.01% 594
2020
Q3
Sell
-19,800
Closed -$531K 1366
2020
Q2
$531K Buy
+19,800
New +$447K ﹤0.01% 1196

Other funds holding HALO

TD Asset Management's HALO Position: Q2 2026 in Review

TD Asset Management reduced its Halozyme (HALO) stake by 4.5% in Q2 2026, selling an estimated $3.61M and leaving 1,115,730 shares worth $87.3M. The position accounts for 0.08% of the portfolio, ranked #205.

TD Asset Management first reported a position in HALO in Q2 2020 and has held it in 16 quarters since. The position peaked at $124M in Q2 2024. 526 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • TD Asset Management held 1,115,730 shares of Halozyme worth $87.3M as of Q2 2026.
  • TD Asset Management sold 52,936 Halozyme shares in Q2 2026, an estimated $3.61M.
  • Halozyme made up 0.08% of TD Asset Management's portfolio in Q2 2026, its #205 holding.
  • TD Asset Management first reported a position in Halozyme in Q2 2020 and has held it in 16 quarters since.
  • TD Asset Management's Halozyme position peaked at $124M in Q2 2024.
  • 526 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.